• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Dyne Therapeutics (DYN)

Common Shares
Sell: $17.30|Buy: $19.50|Change: 0.87 (4.86%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Address

1209 Orange Street
Corporation Trust Center
Wilmington
DE
USA
19801

Website

https://www.dyne-tx.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Dyne Therapeutics Inc Third Quarter Earnings Results for 20262026-11-05T00:00:00
Dyne Therapeutics Inc Second Quarter Earnings Results for 20262026-07-28T00:00:00
Dyne Therapeutics Inc Annual General Meeting for 20262026-05-29T11:00:00
Dyne Therapeutics Inc First Quarter Earnings Results for 20262026-05-08T00:00:00
Dyne Therapeutics Inc Fourth Quarter Earnings Results for 20252026-02-27T00:00:00
Dyne Therapeutics Inc Annual Report for 20252026-02-27T00:00:00

Previous key dates

NameKey Date
Dyne Therapeutics Inc Fourth Quarter Earnings Results for 20252026-02-27T00:00:00
Dyne Therapeutics Inc Annual Report for 20252026-02-27T00:00:00
44(th) Annual J.P. Morgan Healthcare Conference2026-01-14T20:15:00
Topline Clinical Results from the DELIVER Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy2025-12-08T08:00:00
8th Annual Evercore Healthcare Conference2025-12-02T09:35:00
Jefferies Global Healthcare Conference2025-11-17T10:00:00
Stifel 2025 Healthcare Conference2025-11-11T09:20:00
Guggenheim 2nd Annual Healthcare Innovation Conference2025-11-10T10:00:00
Dyne Therapeutics Inc Third Quarter Earnings Results for 20252025-11-05T00:00:00
Morgan Stanley 23rd Annual Global Healthcare Conference2025-09-08T09:15:00
Cantor Global Healthcare Conference 20252025-09-05T09:45:00
Dyne Therapeutics Inc Second Quarter Earnings Results for 20252025-07-28T00:00:00
Dyne Therapeutics Update on DYNE-101 for Myotonic Dystrophy Type 1 Conference Call 20252025-06-17T08:00:00
Dyne Therapeutics Inc Annual General Meeting for 20252025-05-30T11:00:00
Dyne Therapeutics Inc First Quarter Earnings Results for 20252025-05-08T00:00:00
Dyne Therapeutics Inc Fourth Quarter Earnings Results for 20242025-02-27T00:00:00
Dyne Therapeutics Inc Annual Report for 20242025-02-27T00:00:00
Oppenheimer 35th Annual Healthcare Life Sciences Conference2025-02-11T16:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.